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Summary A late phase II clinical trial of RP56976 (docetaxel), derived from Taxus baccata was performed to
evaluate anti-tumour activity, time to progression and clinical toxicity in patients with advanced or recurrent
breast cancer. The patients, between 15 and 80 years old with performance status (PS) of0-2, received at least
two cycles of docetaxel 60 mg m-2 intravenously at 3-4 week intervals. Of the 81 patients enrolled, the 72
eligible for the study were given a total of 327 cycles, with a median of four cycles each. Five patients obtained
a complete response (CR) and 27 a partial response (PR); the response rate (RR) was 44.4% (95% confidence
interval 32.7-56.6%). A relatively high RR of 9/28 (32.1%) was observed in patients who had received prior
chemotherapy involving anthracyclines. The dose-limiting toxicity was grade 3-4 leucocytopenia or
neutropenia, found in 78.9% and 85.9% patients respectively. Other severe (grade>3) toxicities included
alopecia (38%), anorexia (18.3%), nausea/vomiting (11.3%), and fatigue (9.9%). Hypersensitivity reactions,
oedema and skin toxicity were not severe and were reversible. One therapy-related death occurred 10 days after
the initial dose was given. These findings indicate that docetaxel has potent activity against metastatic breast
cancer, and that the dose of 60 mg m-2 is safe.
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The new anti-neoplastic taxoid, RP56976 (docetaxel, N-
debenzoyl-N-tert-bytoxycarbonyl-10-deacetyl taxol), has been
semisynthesised from the precursor (10-deacetylbaccatin III)
derived from the needles of the European yew, Taxus
baccata, by Rhone-Poulenc Rorer and Centre National de
la Recherche Scientifique, France (Ringel and Horwitz, 1991;
Guenard et al., 1993). This agent is an analogue of Taxol
(paclitaxel), but has a more hydrophilic chemical structure
and requires cremophor as a solvent. The docetaxel
formulation was developed with Polysorbate 80 to avoid
the use of cremophor, which had been implicated as a
possible causative agent in the hypersensitivity reactions
(HSRs) seen with paclitaxel (Weiss et al., 1990; Burris et al.,
1993). Docetaxel displays a unique mechanism for induction
of stable microtubule assembly and promotion of tubulin
polymerisation, similar to that of paclitaxel (Ringel and
Horwitz, 1991). Docetaxel has been proven to have potent
cytotoxic activity in experimental in vivo and in vitro studies
(Bissery et al., 1991, Kelland and Abel, 1992).
The clinical anti-neoplastic efficacy of docetaxel has been
studied in phase I and phase II trials in Europe, the United
States and Canada (Burris et al., 1993; Piccart, 1993). In
breast cancer, high response rates to the drug have been
reported by Fumoleau et al. (1993), Seidman et al. (1993),
and Trudeau et al. (1993). Similar response rates have been
reported for paclitaxel by Holmes et al. (1991) and others
(Pazdur et al., 1993). Following these pioneering studies, a
clinical phase I study of the effects of docetaxel in solid
tumours was conducted in Japan (Taguchi et al., 1994a).
Single and repeated dosing of 1 h intravenous (i.v.) infusions
were used, and the maximum tolerated dose (MTD) of
docetaxel was 70-90 mg m-2, with the dose-limiting factor
being leucocytopenia (neutropenia). The recommended dose
for further clinical studies in Japan was 60 mg m-2.
Subsequently, a preliminary phase II study was carried out
in Japan to determine the anti-tumour response and safety of
docetaxel in breast cancer. Docetaxel 60 mg m-2 was given as
a 1 h i.v. infusion, for at least two courses every 3-4 weeks
(Taguchi et al., 1994b). In this study, two complete responses
(CRs) and 19 partial responses (PRs) were obtained in 51
eligible patients, and the overall response rate was 41.2%.
The present phase II clinical trial was, therefore, designed to
confirm the clinical efficacy and tolerability of docetaxel in
patients with advanced or recurrent breast cancer. The same
dose and schedule was used as in the earlier phase II trial, i.e.
60 mg m-2 docetaxel as a 1 h i.v. infusion, given at 3-4
week intervals.
Patients and methods
Eligibility criteria
Patients were registered from 31 hospitals during the 7
months from March to September 1993 (Registration office,
Japanese Society for Cancer Chemotherapy). The majority of
patients had recurrent breast cancer; the remaining patients
who presented with stage ITlb or IV disease were defined as
having advanced disease. Eligibility criteria were as follows:
(1) histologically or cytologically confirmed breast cancer
with evaluable or measurable lesions; (2) patients could have
received adjuvant therapy following mastectomy provided
there was a treatment-free period of >6 months since prior
adjuvant chemotherapy, or > 1 month since prior hormone
therapy; (3) patients could have received one or two
chemotherapy regimens for advanced or relapsed disease;
(4) a wash-out period was required of >4 weeks since prior
chemotherapy, or >2 weeks since receiving biological
response modifiers, hormones, antimetabolites or radio-
therapy (to lesions other than those to be evaluated in the
current study); (5) age 15-80 years; (6) JSCT (Japan Society
for Cancer Therapy) performance status (PS) of 0-2, which
is similar to ECOG PS 0-2; (7) life expectancy more than 3
months after study entry; (8) laboratory parameters of
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leucocyte count 3600-8800 mm-3; neutrophil count
>2000 mm-3; platelet count > 100000 mm-3; haemoglobin
>9.5mgdl-'; total bilirubin <1.5mgdl-1; serum transami-
nases (GOT, GPT) <twice the upper limit of normal for the
hospital (except for patients with hepatic metastasis);
albumin >3.0 g dl1-'; creatinine within normal range for
the hospital.
Dosage andfollow-up observation
RP56976 (docetaxel), was provided by Rhone-Poulenc Rorer
in 2 ml vials as a concentrated solution of 80 mg 2 ml-' in
Polysorbate 80. The patients were given at least two cycles of
docetaxel 60 mg m-2 as a 1 h i.v. infusion. The interval
between cycles of treatment was usually 3-4 weeks.
However, this was prolonged for up to an additional 2
weeks when incomplete recovery was observed in haemato-
logical, blood chemistry and urinary examinations conducted
during the course of treatment. Treatment was stopped if
grade 4 non-haematological side-effects occurred. Tumour
lesions were recorded at least every 3-4 weeks; tumour
markers, CEA, CA15-3 and/or others, were examined every 2
or 4 weeks.
Evaluation of response
The anti-tumour responses were assessed by extramural
review (Appendix 2). Patients with evaluable disease but no
measurable lesions were included. We used the JSCT criteria
(Furue et al., 1986a,b). These are fundamentally similar to
the WHO criteria for evaluating anti-tumour effects and
clinical tolerance. However, patients with evaluable but not
measurable disease were assessable for response. Improve-
ment of bone metastases was defined as a >50%
recalcification or healing of lytic lesions noted on periodical
bone X-rays with the aid of the changes in tumour markers
and radionuclide scan.
This trial was designed in accordance with the Japanese
guidelines for the clinical evaluation of anti-neoplastic drugs
(in Japanese; The Ministry of Health and Welfare, 1992), and
was performed after the approval of the investigational
review board of each hospital was given. A monitoring
committee was arranged independently to assess the
evaluation of safety and efficacy in the study. Informed
consent, usually in writing, was obtained for every patient
before entry. Fifty-five patients entered of their own will, but
the other 26 patients were registered with the approval of a
close relative, i.e. parent, husband, sister, son or daughter.
Direct discussion of the diagnosis and/or prognosis with the
patient was deemed therapeutically and/or psychologically
inappropriate in these cases.
Results
Patients
Of the 81 patients entered in the study, 72 were deemed
eligible, and nine were excluded (Table I). The reasons for
ineligibility were: no evaluable or measurable tumour lesions
(n= 1), three or more prior chemotherapy regimens (n=2), an
unacceptably short period since prior therapy (n=2), drug
treatment with prior registration (n=3) and brain metastasis
(n= 1). Treatment efficacy was assessed by intention to treat
in all 72 eligible patients, although response could not be
determined in three non-evaluable (NE) patients (one due to
non-administration of drug, one early death on day 10, and
one patient refusal); 71 patients were evaluable for toxicity.
The median age of all 72 patients was 53.5 years (range
29-73 years) and median PS was 0. One patient with PS 4
due to pain from bone metastasis, but who was otherwise
well, was included. These 72 patients received a total of 327
cycles of docetaxel, with a median of four cycles each. The
dose of docetaxel was modified for six patients on and after
the second cycle, five received a reduced dose, approxi-
mately 50 mg m-2, due to severe neutropenia (<100 mm-3)
in the prior cycle. The dose was increased to 70 mg m-2 in
one patient, because of good tolerability during the former
cycle.
Anti-tumour activity
The anti-tumour response in all 72 eligible patients is shown
in Table II. The overall response rate was high at 44.4% (32/
72, with 95% CI 32.7-56.6%). The response according to
histological tumour type was principally 37.5% for papillo-
tubular carcinoma, 47.8% for solid tubular carcinoma,
40.9% for scirrhous carcinoma and 66.7% for medullary
carcinoma.
The correlation between prior therapy and response to
docetaxel was examined. The response rate was very high 3/4
Table I Patient characteristics
Patients entered
Patients eligible
Median age (years)
Range
Performance status
0
2
4
Advanced
Recurrent
No prior treatment
Prior treatment
Surgery
Radiotherapy
Chemotherapy
Biological response modifier
Hormonal
Number of lesions (pts)
1
2
3
4
81
72
53.5
29-73
48
15
8
1
9
63
4
68
65
19
62
3
50
31
28
7
6
Table II Responses for advanced or recurrent breast cancer and its metastatic sites
Eligible Response Confidence interval
patients CR PR NC(MR) PD NE rate (%) (95%)
Total response 72 5 27 24 (5) 13 3 44.4 32.7-56.6
Advanced 9 1 3 3 (1) 1 1 44.4 13.7-78.8
Recurrent 63 4 24 21 (4) 12 2 44.4 31.9-57.5
Primary/local 23 6 5 7 (2) 4 1 47.8 26.8-69.4
Lymph nodes 36 8 15 8 (2) 3 2 63.9 46.2-79.2
Lung 23 2 7 10 (1) 3 1 39.1 19.7-61.5
Bone 21 4 12 (1) 2 3 19.0 5.4-41.9
Liver 16 8 7 (5) 1 50.0 24.7-75.3
Other 13 1 7 (1) 3 2 7.7 0.2-36.0
CR, complete response; PR, partial response; NC, no change; MR, minor response; PD, progressive disease; NE, non-evaluable.Phase II study of docetaxel in breast cancer
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Table m Prior therapy for recurrent patients
Eligible Response Confidence interval
Prior therapy patients CR PR NC(MR) PD NE rate (%) (95%)
No prior treatment 2 1 1 50.0 1.3-98.7
Adjuvant chemotherapya 40 3 17 13 (3) 5 2 50.0 33.8-66.2
Including anthracyclinesb 17 10 5 (1) 1 1 58.8 32.9-81.6
Non-anthracyclines 23 3 7 8 (2) 4 1 43.5 23.2-65.5
Prior chemotherapya 42 2 13 17(2) 9 1 35.7 21.6-52.0
Including anthracyclinesb 28 1 8 10 (1) 8 1 32.1 15.9-52.4
Non-anthracyclines 14 1 5 7 (1) 1 42.9 17.7-71.1
Hormone therapy 10 2 6 1 (1) 1 80.0 44.4-97.5
Total dose of anthracyclines/prior
chemotherapyc
Patients 26 1 8 10 6 1
Median dose (mg) 180 345 157.5 475 600
Range (mg) 200-720 40-560 75-864
Median no. of cycles 6 5.5 3 9.5 10
Range 1-12 2-15 1-27
aIncludes combination therapy with hormones and chemotherapeutic agents. bCA, cyclophosphamide, doxorubicin; CAF, CA+5-FU; CA-T,
CA+tamoxifen citrate. cThe total volume of anthracycines was calculated from each volume and total cycles given as prior chemotherpy for
recurrent patients. dExcept two patients treated with unapproved drugs. CR, complete response; PR, partial response; NC, no change; MR, minor
response; NE, non-evaluable.
(75%) in patients who had received no previous systemic
treatment. Similarly, eight of ten (80%) patients previously
treated only with hormone therapy responded to docetaxel
(Table III). Among patients previously treated with
chemotherapy for recurrent disease, the response rate was
similar for those who had received an anthracycline (9/
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Figure 1 Duration of response for each lesion. Each bar
represents median day from initial (left) to terminal (right) of
response duration. M, Duration of response; (: Number of
lesions.
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Figure 2 Time to progression in 64 patients. Of an eligible 72
patients, three dropped out as inevaluable and five were excluded
from the figure because they were retreated with another therapy
before occurrence of progression or newly grown tumour. Median
time to progression was 116 days and 20 patients (31.3%) did not
have any complication of disease (PD) during the test period.
28 = 32%) and those who had not received an anthracycine
(6/14 =43%). The only patient previously treated with two
regimens after recurrence showed PD with docetaxel.
The median duration of response at the end of the study
was 110 days (range 32-214 days). A decrease in tumour size
was often observed in soft tissues (breast or lymph nodes)
after the first cycle of treatment but was somewhat delayed in
parenchymal tissues (Figure 1). The median time to achieve a
response was after the end ofthe second cycle in the liver and
lungs, and after the third cycle in bones. The time to
progression is shown in Figure 2. Of the 72 eligible patients,
eight were not evaluable for time to progression (three who
were NE and five who received other therapy following
completion of the study without confirmation of tumour
progression). The median time to progression in the
remaining 64 patients was 116 days (range 7-239+days).
Neither progression of disease nor new lesions were seen in
20 of the 64 patients (31.3%) during or after the study.
Table IV Toxicity findings according to JSCT gradesa (n=71)
Grade Grades
Event 1 2 3 4 3-4 %
Decrease of haemoglobin 35 12 3 4.2
Leucocytopenia 2 11 42 14 78.9
Neutropenia 1 6 7 54 85.9
Thrombocytopenia 3 1 2 2.8
Alopecia 6 29 27 38.0
Anorexia 16 18 13 18.3
Nausea/vomiting 21 16 8 11.3
Fatigue 22 12 7 0 9.9
Fever 14 20 1 1.4
Erythema/eruption 20 6 1 0 1.4
Peripheral neuropathyb 16 5 2 0 2.8
Diarrhoea 13 5 1 0 1.4
Oedemae 6 7 2 0 2.8
Stomatitis 8 4 2 0 2.8
Pain (arthralgic,
muscular, bone) 7 4 1 0 1.4
Allergy 4 1 0 0 0.0
Pruritus 2 1 0 0 0.0
Skin abrasion 2 0 0 0.0
Renal failure 0 0 0 1 1.4
Phlebitis 0 0 0 1 1.4
Palpitation 1 0 0 0 0.0
Otherd 10 3 1 0 1.4
aRecorded according to the Japan Society for Cancer Therapy
toxicity classification criteria (Furue et al., 1986b). bIncludes
hypesthesia, sensory or taste disorder and sensation of heat. cOne
patient showed pleural effusion (grade 2) accompanied by oedema
(grade 1). dIncludes headache (n=5: grade 1), abdominal pain (n=2:
grade 1, n=2: grade 2), vertigo (n= 1: grade 1), pigmentation (n= 1:
grade 1), tremor (n= 1: grade 1), conjunctivitis (n= 1: grade 2) and
constipation (n= 1: grade 3).
. . . . .Toxicity
Toxicity is shown in Table IV. Leucocytopenia and
neutropenia were the major toxicities of docetaxel, with
grade 3/4 toxicity occurring in 78.9% and 85.9% respectively
of the 71 patients. In 56 patients who had an episode of
leucocytopenia without granulocyte colony-stimulating factor
(G-CSF) treatment, leucocytopenia or neutropenia was brief
and reversible; the median timing of nadir was at days 8-8.5
leucocyte count and days 9-10 (neutrophil) in cycles 1-3
(Figure 3). However, there was no increase in severity in
subsequent cycles, and the leucocyte count recovered 20-24
days after treatment. Thrombocytopenia and anaemia were
seen less frequently. Febrile episodes occurred in 35 patients,
(49.3%), >380C fever accompanying neutropenia occurred in
only eight patients (11.3%).
Alopecia also occurred frequently, being seen in 62/71
patients (87.3%), and was complete (grade 3) in 27 patients
(38%). The incidence of grade 3 anorexia, nausea/vomiting,
and fatigue was in each case less than 20%. Acute HSR, i.e.
face flushing and palpitation, were observed in cycles 1-3 in
one patient, who received a total of six cycles of docetaxel.
Such episodes which were not very severe, were made
tolerable by corticosteroid (hydrocortisone) medication in
the second and third cycles, and disappeared with premedica-
tion of dexamethasone, diphenhydramine and ranitidine
hydrochloride in the subsequent 4-6 cycles.
Oedema occurred in 15 patients (21.1%), and a severe,
grade 3 episode was recorded in one patient each in the
earlier cycles (cycles 1, 3 and 4). Oedema was first
documented after a median of four cycles or 240 mg m-2
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Cycle No. of Median nadir Median Median days Median days
patients days of nadir from nadir to recovery in grade 3-4
First 56(56) 1450(358) 8.5(9) 8.5(9) 2(4)
Second 51(43) 1600(300) 8(10) 12(10.5) 1.5(4)
Third 37(34) 1600(387) 8(10) 14.5(13) 3(3)
Figure 3 Leucocytopenia and neutropenia ofpatients without G-
CSF. Leucocyte count is demonstrated (top) showing first cycle of
56 patients (-0-), second cycle of 51 patients (-El-) and third of
37 patients (-A-) respectively. Neutrophils were also plotted
bottom, as first cycle of 56 patients (-0-), second cycle of 47
patients (-A-) and third of 34 patients (-A-) respectively.
Leucocytopenia was severe but immediately reversible in the first
cycle, and found to be more or less extended in the second and
third cycles. However, the data ofmedian days ofnadir and those
in grade 3 or 4 leucocytopenia and/or neutropenia demonstrated
that they did not cumulatively increase in severity in any period.
Neutropenia followed leucocytopenia as shown by median days of
nadir. Each value and error bar represents mean and s.e.
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of docetaxel. No prophylactic medication was given to
prevent oedema. However, 13 (86.7%) patients received
diuretics (frusemide or spironolactone) therapeutically after
the occurrence of oedema. Skin toxicity involving erythema/
eruptions and/or skin abrasions occurred, but nail changes or
other severe skin toxicity findings were not observed
throughout the study. In terms of cardiac toxicity, mild
palpitations were observed in one patient. Grade 4 phlebitis
at the injection site was observed in one patient, and was
thought to have arisen from drug leakage.
A patient, 67 years of age, who had widespread local and
metastatic disease affecting both lungs, lymph nodes and
bone, died 10 days after her first cycle of 60 mg m-2 (total
78 mg) docetaxel. Clinical signs of diarrhoea and fever of
more than 37°C were noted immediately after dosing.
Stomatitis and severe grade 4 neutropenia subsequently
occurred on days 6 and 7 respectively. Acute renal failure,
characterised by increases in blood urea nitrogen (BUN) and
creatinine values, was detected 9 days before the occurrence
of dyspnoea, but recovered temporarily with diuretic
treatment. Death was attributed to pulmonary congestion
accompanying grade 4 acute renal failure.
Discussion
The efficacy of docetaxel, 60 mg m-2 dose, in breast cancer
has previously been demonstrated. A response rate of 42%
was reported in patients who had not responded to standard
chemotherapy in an early phase II clinical trial in Japan
(Taguchi et al., 1994b). Subsequently, two independent multi
centre late phase II studies, consisting of two different groups
(A and B) have been conducted. These studies were the same
in design and evaluated by the same review board
determining patient eligibility and anti-tumour response.
The present study (group B) with a response rate of 44%
confirmed that 60 mg m-2 of docetaxel was effective in
patients with advanced or recurrent breast cancer. In another
late phase II trial (group A) a similar high response rate of
52.2% has been reported (Taguchi et al., 1994c).
Seidman et al. (1993) reported a high potency, i.e. a
response rate of 57% (8/14), in patients with metastatic
breast cancer. This phase II study in the USA used docetaxel
100 mg m-2 administered as a 1 h i.v. infusion as first-line
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Figure 4 Occurrence of peripheral oedema. Peripheral oedema
occurred in 15 patients. Oedema was not intensified in severity by
repeated dosage, while the incidence (%) increased as a result of
fewer patients in later cycles. Columns represent total patients
(E), and patients with grade 1-2 (M) or grade 3 (_)
oedema.
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chemotherapy. A similar response rate, 57% (12/21), was
achieved with the same dose in Canada (Trudeau et al.,
1993). In EORTC phase II studies of patients with advanced
breast cancer, Fumoleau et al. (1993) reported a higher
response rate of 73% (24/33) with the 100 mg m-2 dose. By
contrast, Dieras et al. (1994) recently reported a response rate
of 50.0% with 75 mg m-2 docetaxel given without any
premedication. Therefore, anti-tumour activity of this agent
probably depends on the dose, a higher dose close to the
MTD clinically more effective. However, in the Japanese
clinical trials, a lower dose of 60 mg m-2 was recommended.
Doses of 70 mg m-2 or higher were rejected as this was the
MTD in our phase I study (Taguchi et al., 1994a). Generally
in Japanese patients, the combination of cyclophosphamide
(CPA)-doxorubicin (DOX) with or without 5FU or CPA-
methotrexate-5FU, is used as first-line chemotherapy. These
regimens have been demonstrated as highly effective against
metastatic and recurrent breast cancer (Kanda et al., 1981;
Kubo et al., 1983). However, the duration of response is
relatively short, 8-12 months, and there are few if any anti-
neoplastic drugs active as second- or third-line chemotherapy
against DOX-resistant cancer. The present study demon-
strated that the response rate in patients who had received
prior DOX chemotherapy was little different from that in
patients not exposed to anthracyclines. This relatively high
potency is notable in comparison with other drugs used in
patients after prior DOX therapy, strongly indicating that
docetaxel is a candidate for second-line chemotherapy of
DOX-resistant breast cancer.
The median duration of response and median time to
progression, each approximately 3 months, were similar to
those reported in the EORTC phase II study (Fumoleau et
al., 1993). We believe that the results of the current study are
better than those achieved with standard chemotherapy, since
docetaxel was used as second-line treatment in the majority
of patients (94.4%). Gregory et al. (1993) demonstrated in
their extensive study of 1756 breast cancer patients that the
median duration of response was 7.8 months and the median
time to progression was 3.7 months with first-line
chemotherapy. However, after two or more chemotherapy
regimens these periods were significantly shortened to 2.3
months. Further studies will be required to evaluate the
impact on survival and/or quality of life of docetaxel as first-
line chemotherapy in recurrent breast cancer.
The dose-limiting toxicity of docetaxel has already been
demonstrated to be leucocytopenia or neutropenia in phase I
and early phase II studies in Japan (Taguchi et al., 1994a,b).
Similarly, episodes of neutropenia were found to be severe
but reversible and of brief duration in the present study.
Additionally, there was a small proportion of patients who
developed febrile neutropenia on treatment with a dose of
60 mg m-2. G-CSF was administered to them and the
recovery time was shortened, despite the severity of the
neutropenia.
In the present study, we also found mild HSR effects, such
as skin rash and pruritus, and one patient had acute HSR.
HSR has been reported in a phase I study of docetaxel, and
Burris et al. (1993) proposed that HSR might be due to the
basic 'taxane' molecule itself. In the EORTC study, Wanders
et al. (1993) reported HSR following docetaxel in 27% of the
337 patients. However it recovered upon discontinuation of
the infusion and appropriate therapy with corticosteroids,
anti-histamines and H2-antagonists. A patient having acute
HSR in the present study was able to continue receiving the
docetaxel when the dosing interval was prolonged or with the
administration of steroid. Moreover, HSR was also prevented
by prophylactic medication with steroids and H1- and H2-
antagonists in the following cycles. Thus, we believed that
HSR was mild and tolerable at a dose of 60 mg m-2 of
docetaxel.
The incidence of oedema in this study was 21.1%. Oedema
has been reported to be cumulative, since it has been detected
after several (5-6) cycles in previous studies (Fumoleau et
al., 1993; Piccart 1993). Oedema after treatment with
docetaxel has been divided into two distinct types. Firstly,
angioedemea, which is responsive to corticosteroids; secondly
a fluid retention syndrome, manifesting as peripheral oedema
or pleural effusion that is responsive to diuretics (Pazdur et
al., 1993). In the present study episodes of oedema seemed to
be of the latter type, i.e. peripheral oedema, which was
tolerable and reversible on diuretic treatment. Oedema
appears to have occurred after fewer cycles and a lower
docetaxel dose than reported using the 100 mg m-2 dose. The
development of oedema probably depends on the number of
cycles rather than the total amount of the agent. The reason
for the apparently earlier occurrence of oedema may be that
few patients received a large number of cycles of docetaxel.
Oedema occurred repeatedly in a few patients, but did not
increase in severity. Therefore, the patients who had
peripheral oedema were able to continue treatment with
docetaxel.
The therapy-related death in this study was considered to
be a result of severe dyspnoea accompanying acute renal
failure. The precise relationship between the death and the
acute renal failure is not yet known. However, dyspnoea has
been suggested to be related to an increase of pleural fluid
arising from pleurisy with bilateral pulmonary metastasis and
drug-related oedema.
The recent EORTC phase II study recommended a
docetaxel dose of 100 mg m-2 since the activity is greater
than, but the safety profile similar to, that for a dose of
75 mg m-2 (Dieras et al., 1994). However, in the current
study toxicity was mild using lower doses of docetaxel.
Neutropenia was marked but reversible; there was a low
incidence of HSR and/or oedema, which were tolerable
without any prophylactic medication. Moreover, ethically
and clinically we could not use higher doses of docetaxel
given the results of phase I trials in Japan. In conclusion, we
found a dose of 60 mg m-2 of docetaxel without premedica-
tion to be sufficient in terms of clinical activity and
tolerability for advanced or recurrent breast cancer.
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